| Autor: |
Li-hui, Ren, Jian-jun, Peng, Hui-ming, Ye, Zuo-yan, Wang, Ce, Chen |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
Zhonghua yi xue za zhi. 92(28) |
| ISSN: |
0376-2491 |
| Popis: |
To evaluate the clinical outcomes of high-dose tirofiban in patients with ST-elevation myocardial infarction (ASTEMI) undergoing primary percutaneous coronary intervention (PCI).A total of 104 consecutive ASTEMI patients undergoing primary PCI were enrolled from January 2010 to February 2011. They were randomized into the high-dose tirofiban group (n = 52) and the normal-dose tirofiban group (n = 52). We measured the sumST-segment resolution of ECG post-PCI respectively and left ventricular ejective fraction (LVEF) at Day 90 post-PCI.After PCI, the sumST-segment resolution of ECG of the high-dose tirofiban group significantly improved than that of the normal-dose tirofiban group (38% ± 12% vs 34% ± 13%, P0.05). Before PCI, LVEF of two groups is 50.2% ± 1.4% vs 49.6% ± 1.1% (P0.05), but at day 90 post-PCI, LVEF had significant difference between two groups (60.1% ± 1.1% vs 56.0% ± 1.2%, P0.05). The rates of major and moderate hemorrhage did not differ significantly between two groups.High-dose tirofiban improves myocardial reperfusion and clinical outcome. It re-emphasizes the importance of further platelet aggregation inhibition in ASTEMI patients undergoing primary PCI. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
